

Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza
Newark, New Jersey 07102-5490
(973) 286-6700
clizza@saul.com

*Attorneys for Plaintiff
Celgene Corporation*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

CELGENE CORPORATION,)	
)	Civil Action No. _____
Plaintiff,)	
)	COMPLAINT FOR PATENT
v.)	INFRINGEMENT
)	
BARR LABORATORIES, INC. and)	(Filed Electronically)
BARR PHARMACEUTICALS, INC.,)	
)	
Defendants.)	
)	

Plaintiff Celgene Corporation (“Celgene”), by its undersigned attorneys, brings this action against defendants, Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc., for patent infringement and alleges as follows:

Nature of the Action

1. This is an action for patent infringement under the patent laws of the United States, 35 United States Code, arising from Barr Laboratories, Inc.’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”) seeking approval to commercially market a generic version of Celgene’s Thalomid® brand drug prior to the expiration of certain patents owned by Celgene that cover that product’s

use, *i.e.*, United States Patent Nos. 6,045,501 (“the ’501 patent”), 6,315,720 (“the ’720 patent”), 6,561,976 (“the ’976 patent”), 6,561,977 (“the ’977 patent”), 6,755,784 (“the ’784 patent”), 6,869,399 (“the ’399 patent”), and 7,141,018 (“the ’018 patent”) (collectively, “the patents-in-suit”).

The Parties

2. Plaintiff Celgene is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 86 Morris Avenue, Summit, New Jersey 07901.

3. On information and belief, defendant Barr Laboratories, Inc. is a corporation having its principal place of business at 223 Quaker Road, Pomona, New York 10970.

4. On information and belief, defendant Barr Pharmaceuticals, Inc. is a corporation organized and existing under the laws of the State of Delaware, having a place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677.

5. On information and belief, defendant Barr Laboratories, Inc. is a subsidiary of defendant Barr Pharmaceuticals, Inc.

6. On information and belief, Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc. are registered to do business in New Jersey. Further, on information and belief, Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc. maintain executive offices and a manufacturing facility and otherwise transact business within this District.

7. On information and belief, the acts of Barr Laboratories, Inc. complained of herein were done at the direction of, with the authorization of, or with the cooperation, participation, or assistance of, or at least in part for the benefit of, Barr Pharmaceuticals, Inc.

8. Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc. are referred to hereinafter, collectively, as “Barr.”

Jurisdiction and Venue

9. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a) and 2201 and 2202.

10. This Court has personal jurisdiction over Barr by virtue of the fact that Barr has availed itself of the laws of New Jersey and conducts business in New Jersey.

11. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391 and 1400(b).

The Patents in Suit

12. On April 4, 2000, the United States Patent and Trademark Office (“USPTO”) duly and lawfully issued the ’501 patent, entitled “Methods for Delivering a Drug to a Patient While Preventing the Exposure of a Foetus or Other Contraindicated Individual to the Drug” to Celgene as assignee of the inventors Marc Elsayed and Bruce Williams. A copy of the ’501 patent is attached hereto as Exhibit A.

13. On November 13, 2001, the USPTO duly and lawfully issued the ’720 patent, entitled “Methods for Delivering a Drug to a Patient While Avoiding the Occurrence of an Adverse Side Effect Known or Suspected of Being Caused by the Drug” to Celgene as assignee of the inventors Bruce A. Williams and Joseph K. Kaminski. A copy of the ’720 patent is attached hereto as Exhibit B.

14. On May 13, 2003, the USPTO duly and lawfully issued the ’976 patent, entitled “Methods for Delivering a Drug to a Patient While Preventing the Exposure of a Foetus or Other Contraindicated Individual to the Drug” to Celgene as assignee of the inventors Marc Elsayed and Bruce Williams. A copy of the ’976 patent is attached hereto as Exhibit C.

15. On May 13, 2003, the USPTO duly and lawfully issued the '977 patent, entitled "Methods for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May be Contraindicated" to Celgene as assignee of the inventors Bruce A. Williams and Joseph K. Kaminski. A copy of the '977 patent is attached hereto as Exhibit D.

16. On June 29, 2004, the USPTO duly and lawfully issued the '784 patent, entitled "Methods for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May be Contraindicated" to Celgene as assignee of the inventors Bruce A. Williams and Joseph K. Kaminski. On May 3, 2005, a certificate of correction was granted by the USPTO to correct a typographical error in claim 29 of the '784 patent. A copy of the '784 patent and its certificate of correction is attached hereto as Exhibit E.

17. On March 22, 2005, the USPTO duly and lawfully issued the '399 patent, entitled "Methods for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May be Contraindicated" to Celgene as assignee of the inventors Bruce A. Williams and Joseph K. Kaminski. On March 7, 2006, a certificate of correction was granted by the USPTO to correct typographical errors in claim 19 of the '399 patent. A copy of the '399 patent and its certificate of correction is attached hereto as Exhibit F.

18. On November 28, 2006, the USPTO duly and lawfully issued the '018 patent, entitled "Methods for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May be Contraindicated" to Celgene as assignee of the inventors Bruce A. Williams and Joseph K. Kaminski. A copy of the '018 patent is attached hereto as Exhibit G.

The THALOMID[®] Drug Product

19. Celgene holds an approved New Drug Application (“NDA”) under Section 505(a) of the Federal Food Drug and Cosmetic Act (“FFDCA”), 21 U.S.C. § 355(a) for thalidomide capsules (NDA No. 20-785), which it sells as THALOMID[®] brand drug. The claims of the ’501, ’720, ’976, ’977, ’784, ’399, and ’018 patents cover, *inter alia*, methods of use and delivery of pharmaceutical compositions containing the drug thalidomide.

20. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the ’501, ’720, ’976, ’977, ’784, ’399, and ’018 patents are listed in the FDA publication, “Approved Drug Products with Therapeutic Equivalence Evaluations” (the “Orange Book”), with respect to THALOMID[®] brand drug.

Acts Giving Rise to this Suit

21. Pursuant to Section 505 of the FFDCA, Barr filed ANDA No. 78-505 for thalidomide capsules, seeking approval to engage in the commercial use, manufacture, sale, offer for sale or importation into the United States of thalidomide capsules before the patents-in-suit expire.

22. On October 4, 2007, Barr amended its ANDA to seek approval to engage in the commercial use, manufacture, sale, offer for sale or importation into the United States of 150 mg thalidomide capsules (“Barr’s Proposed Product”) before the patents-in-suit expire.

23. After amending its ANDA, Barr was required to send Celgene notification pursuant to 21 U.S.C. § 355(j)(2)(B)(ii).

24. No earlier than October 4, 2007, Barr sent written notice of its amended ANDA to Celgene (“Barr’s Notice Letter”). In its Notice Letter, Barr alleged that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by Barr. Barr’s Notice Letter also informed

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.